T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1

Malika Trad, Alexandrine Gautheron, Jennifer Fraszczak, Darya Alizadeh, Claire Larmonier, Collin J. Lacasse, Sara Centuori, Sylvain Audia, Maxime Samson, Marion Ciudad, Francis Bonnefoy, Stéphanie Lemaire-Ewing, Emmanuel Katsanis, Sylvain Perruche, Philippe Saas, Bernard Bonnotte

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

T lymphocytes activated by dendritic cells (DC) which present tumor antigens play a key role in the antitumor immune response. However, in patients suffering from active cancer, DC are not efficient at initiating and supporting immune responses as they participate to T lymphocyte inhibition. DC in the tumor environment are functionally defective and exhibit a characteristic of immature phenotype, different to that of DC present in nonpathological conditions. The mechanistic bases underlying DC dysfunction in cancer responsible for the modulation of T-cell responses and tumor immune escape are still being investigated. Using two different mouse tumor models, we showed that tumor-infiltrating DC (TIDC) are constitutively immunosuppressive, exhibit a semimature phenotype, and impair responder T lymphocyte proliferation and activation by a mechanism involving CD39 ectoenzyme.

Original languageEnglish (US)
Article number891236
JournalBioMed research international
Volume2015
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1'. Together they form a unique fingerprint.

Cite this